MedTrace Logo

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-12-26

Study results available
· View outcomes & findings →

Summary

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)

Conditions

Interventions

DRUG

CX-072

CX-072 in combination with ipilimumab

DRUG

Ipilimumab

CX-072 in combination with ipilimumab

Sponsors & Collaborators

  • CytomX Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lawrence Lu, MD · CytomX Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-20
Primary Completion
2020-05-21
Completion
2020-05-21
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Netherlands
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03993379 on ClinicalTrials.gov